The market for biotech IPOs is experiencing its best run in nine years, with 16 companies...
Jul 2 2013, 07:02 ET
The market for biotech IPOs is experiencing its best run in nine years, with 16 companies raising $1.1B in H1. An increase in FDA drug approvals, a strong performance by some biotech firms that are already listed, and the JOBS Act, which allows companies to privately "test the waters" before publicly launching an IPO process, are some of the factors behind the trend. Companies to benefit include heart-drug company Esperion Therapeutics (ESPR), and Prosensa Holding (RNA), a developer of treatments for rare diseases.